Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/17515
Title: | Anticompetitive Patent Acquisitions in the Pharmaceutical Industry |
Authors: | Gurgula, O |
Keywords: | pharmaceutical patents;patent acquisitions;Perindopril;Bioval;anticompetitive behaviour;monopolisation;abuse of dominant position |
Issue Date: | 7-Feb-2018 |
Publisher: | SSRN |
Citation: | ECLR: European Competition Law Review, 2017, 38 (1), pp. 35 - 38 (4) |
Abstract: | Pharmaceutical companies use various strategies to protect their market monopoly. One of such practices is an acquisition of a patent developed by a third party. Such acquisitions allow pharmaceutical companies to strengthen their market power by extending the life of the product; for instance, by acquiring patents that cover alternative non-infringing versions of the monopolist’s own product, or acquiring the patent that covers an improvement of its current product. Both the US and EU case law condemn such practices as an abuse of monopoly power. This Article discusses patent acquisitions in the pharmaceutical industry focusing on two recent EU and US cases investigated by the competition authorities. |
URI: | http://bura.brunel.ac.uk/handle/2438/17515 |
ISSN: | 0144-3054 |
Appears in Collections: | Law |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | 488.6 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.